# Yew Bio-Pharm Group, Inc.

Yew Bio-Pharm Group, Inc. is a company headquartered in El Monte, CA, United States.

## Company overview

- **Legal name:** Yew Bio-Pharm Group, Inc.
- **Classification:** Company
- **Industry (SIC):** 0100 — Agricultural Production-Crops
- **Headquarters:** El Monte, CA, United States
- **Incorporated in:** NV
- **Fiscal year end:** December 31
- **SEC CIK:** 0001548240

## About

Yew Bio-Pharm Group, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001548240, and its reported industry is Agricultural Production-Crops. In 10-K filed on 2021-03-30, it reported annual revenue of USD 27,307,687; net income of USD 1,464,882; total assets of USD 58,446,662 for the fiscal period ended 2020-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2020 (period ended 2020-12-31)

- **Revenue:** $27.3M (USD 27,307,687)
- **Net income:** $1.5M (USD 1,464,882)
- **Total assets:** $58.4M (USD 58,446,662)
- **Cash and equivalents:** $563,792 (USD 563,792)
- **Operating cash flow:** $17.3M (USD 17,340,086)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $27.9M (USD 27,883,649)
- **Net income:** $985,506 (USD 985,506)
- **Total assets:** $54.2M (USD 54,206,717)
- **Cash and equivalents:** $742,294 (USD 742,294)
- **Operating cash flow:** $12.0M (USD 11,953,657)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $37.6M (USD 37,596,942)
- **Net income:** -$1.3M (USD -1,322,441)
- **Total assets:** $49.7M (USD 49,692,066)
- **Cash and equivalents:** $521,670 (USD 521,670)
- **Operating cash flow:** $32.5M (USD 32,466,961)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $40.5M (USD 40,539,690)
- **Net income:** $3.2M (USD 3,213,034)
- **Total assets:** $52.9M (USD 52,930,095)
- **Cash and equivalents:** $859,830 (USD 859,830)
- **Operating cash flow:** -$2.6M (USD -2,620,269)

## Recent SEC filings

- Form 8-K — filed 2022-03-29 — period 2022-03-28
- Form 10-Q — filed 2021-11-15 — period 2021-09-30
- Form 10-Q — filed 2021-08-16 — period 2021-06-30
- Form 8-K — filed 2021-07-27 — period 2021-07-27
- Form 10-Q — filed 2021-05-17 — period 2021-03-31
- Form 10-K — filed 2021-03-30 — period 2020-12-31
- Form 8-K — filed 2021-01-05 — period 2021-01-03
- Form 10-Q — filed 2020-11-13 — period 2020-09-30
- Form 8-K — filed 2020-09-15 — period 2020-09-11 — CURRENT REPORT
- Form 10-Q — filed 2020-08-14 — period 2020-06-30 — QUARTERLY REPORT
- Form 10-Q — filed 2020-06-29 — period 2020-03-31 — QUARTERLY REPORT
- Form 8-K — filed 2020-05-15 — period 2020-05-15 — CURRENT REPORT

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/yew-bio-pharm-group-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology